Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 2/20 | 0.68 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5808443 | 0.89 | MTOR (0.82) | MTORABCC1ALDH1A1CA12CA1 | |
| SCHEMBL12994640 | 0.86 | MTOR (0.70) | MTORABCC1ALDH1A1CA12CA1 | |
| SCHEMBL11149211 | 0.84 | ALDH1A1 (0.78) | TMEM97SIGMAR1TSHRALDH1A1NPSR1 | |
| SCHEMBL29140953 | 0.82 | MTOR (0.65) | MTORABCC1ALDH1A1RAB9ANPY5R | |
| SCHEMBL29140936 | 0.80 | MTOR (0.78) | MTORABCC1ALDH1A1CA12CA1 | |
| SCHEMBL29140925 | 0.79 | MTOR (0.61) | MTORABCC1CA12CA1CA2 | |
| SCHEMBL26345898 | 0.79 | RAB9A (0.59) | TMEM97SIGMAR1ALDH1A1CA12CA9 | |
| SCHEMBL11616076 | 0.79 | SMN1; SMN2 (0.57) | MTORTSHRALDH1A1RAB9ANPC1 | |
| SCHEMBL10767909 | 0.79 | TSHR (0.68) | TSHRALDH1A1NPSR1RAB9ANPC1 | |
| SCHEMBL11168593 | 0.79 | MTOR (0.71) | MTORABCC1ALDH1A1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183292-B2 | Chiral cyclic β-amino acids and their derivatives, pharmaceutical compositions containing them and the use of such compounds | BIOBLOCKS MAGYARORSZAG GYOGYSZERKEMIAI ES FEJLESZTO KFT. (HU) | 2012-05-22 | — | — | US | disclosed |
| EP-2102147-B1 | Chiral cyclic beta-amino acids and their derivates, pharmaceutical compositions containing them and the use of such compounds | BIOBLOCKS MAGYARORSZAG GYOGYSZERKEMIAI ES FEJLESZTO KFT (HU) | 2011-06-22 | — | — | EP | disclosed |
| US-20100081717-A1 | Chiral Cyclic Beta-Amino Acids and their Derivatives, Pharmaceutical Compositions Containing Them and the Use of Such Compounds | BIOBLOCKS MAGYARORSZÁG GYÓGYSZERKÉMIAI ÉS FEJLESZTÖ KFT. (HU) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081717-A1 | Chiral Cyclic Beta-Amino Acids and their Derivatives, Pharmaceutical Compositions Containing Them and the Use of Such Compounds | HRH3, SLC43A1, HRH4 | MTOR 1014/4885TMEM97 754/4885SIGMAR1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.